Progressive MS Model
Multiple Sclerosis (MS) is the most common cause of non-traumatic neurological disability among young adults. Greater than 65% of relapsing/remitting MS patients (RRMS) eventually transition into a disease state where neurological decline is irreversible and continuous. Therapies are not available for these secondary progressive MS (SPMS) patients. A limiting factor in the development of therapies for SPMS patients is the lack of an animal model that shows progressive neurological decline. Renovo conducted a study that proposed a novel rodent model of SPMS via cuprizone and rapamycin treatment. Following treatment, behavioral testing was performed followed by neurohistology. Results showed that animals subjected to multiple episodes (TH) of demyelination demonstrate significant progressive long-term motor deficits and fatigue. The total number of myelinated axons per unit volume of corpus callosum (CC) was 5-times lowers in TH animals compared to CNT, which demonstrates significant axonal loss in CC. Significant loss of OPCs and OLs following three episodes of demyelination. The behavioral deficits and white matter atrophy in this model resemble key features of progressive MS, suggesting this may be a promising new model. Future studies will be conducted to determine if one or two episodes of demyelination will result in the same behavioral and structural differences.
Click here to see the full study from our poster at the 2015 ECTRIMS conference.